E43 Multisystem inflammatory syndrome in children: an experience from Batna –Algeria

Abstract Introduction Multisystem Inflammatory Syndrome in Children (MIS-C) is a new phenomenon reported worldwide with temporal association with Covid-19. MIS-C is defined as a clinically serious condition requiring hospitalization with fever, multi-system organ dysfunction, inflammatory biomarkers increase. Objectives The aim of this study was to describe the demographic, clinical features, therapeutic aspects, complications, and outcomes of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in our region. Methods A retrospective descriptive study was conducted in the COVID-19 area of the Department of Pediatrics of the university hospital center (CHU Benflis Touhami Batna) over a three-year period from March 2019 to March 2022. Demographic and clinical data were collected. Results As at April 01, 2022, a total of 24 patients were hospitalized for MIS-C in our COVID-19 area of the Department of Pediatrics. The mean age was 5 years [3 months to 15 years]; 58% were male. The most common presenting symptoms were fever (88%), rash (60%), conjunctival injection (56%). 45% had gastrointestinal symptoms and 33% had respiratory symptoms. Elevated levels of C-reactive protein, d-dimer, and procalcitonin were found in 80%, 63%, and 50% of the patients, respectively. For treatment, intravenous immunoglobulin was used in 11 (46%), corticosteroids in 18 (75%). All patients were discharged home. Conclusion the incidence of MIS-C among children infected with SARS-CoV-2 is unclear as children often present with mild symptoms of Covid-19. This serious disease condition requires more surveillance and study. Disclosure statement: None declared.